Goldfinch Bio announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will present at the 2019 Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019, at 10:00 a.m. ET in New York.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will present at the 2019 Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019, at 10:00 a.m. ET in New York.
About Goldfinch Bio
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney diseases. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney diseases. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005010/en/
Contacts
The Yates Network
Gina Nugent 617-460-3579
gina@theyatesnetwork.com
Source: Goldfinch Bio
View this news release online at:
http://www.businesswire.com/news/home/20190401005010/en
